Table 3.
Patient subseta | Median PFS (months) | HR (95 % CI) | Log-rank P | |
---|---|---|---|---|
Sunitinib | IFN-α | |||
VEGF-A | ||||
<Median | 13.7 | 7.8 | 0.148 (0.038–0.579) | 0.0019 |
≥Median | 10.9 | 3.9 | 0.451 (0.149–1.36) | 0.150 |
VEGF-C | ||||
<Median | 13.7 | 5.1 | 0.190 (0.059–0.617) | 0.0022 |
≥Median | 11.1 | 7.8 | 0.551 (0.156–1.94) | 0.348 |
sVEGFR-3 | ||||
<Median | 21.7 | 5.4 | 0.122 (0.024–0.615) | 0.0034 |
≥Median | 10.9 | 3.9 | 0.406 (0.147–1.12) | 0.0719 |
IL-8 | ||||
<Median | 21.7 | 7.8 | 0.247 (0.077–0.787) | 0.0114 |
≥Median | 13.7 | 2.6 | 0.403 (0.12–1.35) | 0.131 |
CI confidence interval, HR hazard ratio, IL-8 interleukin-8, IFN-α interferon-alpha, PFS progression-free survival, VEGF-A vascular endothelial growth factor A, VEGF-C vascular endothelial growth factor C, sVEGFR-3 soluble vascular endothelial growth factor receptor 3
aTotal N = 33 and N = 30 for each protein in the sunitinib and IFN-α arms, respectively, apart from IL-8, where total N = 31 and N = 29 in the sunitinib and IFN-α arms, respectively